Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma

Taylor and Francis Group, Leukemia & Lymphoma, 7(64), p. 1315-1321, 2023

Journal article published in 2023 by Nidhi Sharma, Evan Benson, Qiuhong Zhao, Jordan Nunnelee, Francesca Cottini, Patrick Elder, Ashley Rosko, Naresh Bumma, Abdullah Khan

, Elvira Umyarova, Srinivas Devarakonda, Yvonne A. Efebera, Don M. Benson

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m<sup>2</sup> versus 200mg/m<sup>2</sup> preparative regimens in patients with multiple myeloma